N/A
Completed N=8,314
E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent
Source: ClinicalTrials.gov NCT00623441 ↗Enrolled (actual)
8,314
Serious AEs
1.7%
Results posted
Dec 2011
Primary outcomePrimary: MACE (Major Adverse Cardiac Events) — 7.5 Percentage of participants
Summary
The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis.
This prospective multi-center study has been initiated:
* To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation.
* To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MACE (Major Adverse Cardiac Events) |
7.5 | — |
Eligibility Criteria
Inclusion Criteria
- Patient is >18 years of age (or minimum age as required by local regulation)
- The patient has consented to participate by signing the "Patient Informed Consent Form" and/or has authorized the collection and release of his medical information by signing the "Patient Data Release Consent Form".
- The patient is suitable for implantation of one or more Endeavor(TM) ABT-578 Eluting Coronary Stent System in one or more native artery target lesions.
- Lesion length and vessel diameter of the target lesion(s) are according to the "Indications for Use" as mentioned in the "Instructions for Use" that comes with every Endeavor(TM) ABT-578 Eluting Coronary Stent System.
- The patient is willing and able to cooperate with registry procedures and required follow up visits.
Exclusion Criteria
- Women with known pregnancy or who are lactating.
- Patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as ABT-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
- Patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated.
- Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
- Current medical condition with a life expectancy of less than 12 months.
- The subject is participating in another device or drug study. Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. The subject may only be enrolled in this E-five registry once.
- Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry.
Data sourced from ClinicalTrials.gov (NCT00623441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.